These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer. Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA; N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544 [TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222 [TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274 [TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022. André T; Cohen R; Salem ME Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834 [TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636 [TBL] [Abstract][Full Text] [Related]
10. CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors. Ziranu P; Pretta A; Pozzari M; Maccioni A; Badiali M; Fanni D; Lai E; Donisi C; Persano M; Gerosa C; Puzzoni M; Bardanzellu F; Ambu R; Pusceddu V; Dubois M; Cerrone G; Migliari M; Murgia S; Spanu D; Pretta G; Aimola V; Balconi F; Murru S; Faa G; Scartozzi M Sci Rep; 2023 Mar; 13(1):4397. PubMed ID: 36928082 [TBL] [Abstract][Full Text] [Related]
11. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. Fucà G; Cohen R; Lonardi S; Shitara K; Elez ME; Fakih M; Chao J; Klempner SJ; Emmett M; Jayachandran P; Bergamo F; García MD; Mazzoli G; Provenzano L; Colle R; Svrcek M; Ambrosini M; Randon G; Shah AT; Salati M; Fenocchio E; Salvatore L; Chida K; Kawazoe A; Conca V; Curigliano G; Corti F; Cremolini C; Overman M; Andre T; Pietrantonio F J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110358 [TBL] [Abstract][Full Text] [Related]